Skip to content

Integra LifeSciences IART Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
Stryker logo
StrykerSYK
Axogen logo
AxogenAXGN
Globus Medical logo
Globus MedicalGMED
AbbVie logo
AbbVieABBV
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's deferred tax assets and other non-current assets?
Integra LifeSciences (IART) reported deferred tax assets and other non-current assets of $34.96M in Q1 2026.
How has Integra LifeSciences's deferred tax assets and other non-current assets changed year-over-year?
Integra LifeSciences's deferred tax assets and other non-current assets decreased by 34.3% year-over-year, from $53.2M to $34.96M.
What is the long-term trend for Integra LifeSciences's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Integra LifeSciences's deferred tax assets and other non-current assets has grown at a 27.4% compound annual growth rate (CAGR), from $11.28M to $37.88M.